<DOC>
	<DOCNO>NCT00838383</DOCNO>
	<brief_summary>This multi-center , randomize study sitaxsentan administer intravenously subject undergo elective CABG , cardiac valve replacement , combine CABG cardiac valve replacement procedure require CPB .</brief_summary>
	<brief_title>Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery</brief_title>
	<detailed_description />
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Has identify coronary artery bypass grafting ( CABG ) , aortic and/or mitral valve replacement , combine CABG cardiac valve replacement procedure require cardiopulmonary bypass ( CPB ) . Requires emergent `` emergency '' CABG and/or cardiac valve replacement .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>multi-center , placebo-controlled , randomize study sitaxsentan administer subject post-cross-clamp release 12 hour post-CPB</keyword>
</DOC>